Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)-Reference-Cited by-同舟云学术

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

Published:2019-11-29 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Ascierto Paolo A.^ORCID,Bifulco Carlo,Buonaguro Luigi,Emens Leisha A.,Ferris Robert L.,Fox Bernard A.,Delgoffe Greg M.,Galon Jérôme,Gridelli Cesare,Merlano Marco,Nathan Paul,Odunsi Kunle,Okada Hideho,Paulos Chrystal M.,Pignata Sandro,Schalper Kurt A.,Spranger Stefani,Tortora Giampaolo,Zarour Hassane,Butterfield Lisa H.,Puzanov Igor

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0798-3.pdf

Reference77 articles.

1. Matulonis UA, Shapira-Frommer R, Santin A, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study. J Clin Oncol. 2018;36(15 suppl):5511.

2. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109–19.

3. Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol. 2014;193:5327–37.

4. Odunsi K, Cristea MC, Dorigo O, Jazaeri AA, Slomovitz BM, Chagin K, et al. A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891). J Clin Oncol. 2017;35(15 suppl). https://doi.org/10.1200/JCO.2017.35.15 .

5. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–5.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TRP Family Genes Are Differently Expressed and Correlated with Immune Response in Glioma;Brain Sciences;2022-05-19

2. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma;Frontiers in Endocrinology;2022-03-29

3. Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer;Journal of Medical Biochemistry;2022

4. The diterpenoid adenanthin upregulates the expression of natural killer group 2D receptor ligands in hepatocellular carcinoma cells;Molecular and Cellular Probes;2021-10

5. Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients;Frontiers in Pharmacology;2021-08-27